Citations

Mayo Clinic

Showing 10 of 108572 citations.

ACG Clinical Guideline: Alcohol-Associated Liver Disease
Jophlin, Loretta , Shah, Vijay H. , Jophlin, Loretta L , Singal, Ashwani K. , Bataller, Ramon A , Wong, Robert J. , Sauer, Bryan G. , Terrault, Norah A.

American Journal of Gastroenterology | January 4, 2024 | Volume: 119 | Issue: 1 | Pages: 30-54

10.14309/ajg.0000000000002572 | PMID 38174913 Get It

ABSTRACT Alcohol-associated liver disease (ALD) is the most common cause of advanced hepatic disease and frequent indication for liver transplantation worldwide. With harmful alcohol use as the primary risk factor, increasing alcohol use over the past decade has resulted in rapid growth of the ALD-related healthcare burden. The spectrum of ALD ranges from early asymptomatic liver injury to advanced disease with decompensation and portal hypertension. Compared with those with other etiologies of liver disease, patients with ALD progress faster and more often present at an advanced stage. A unique phenotype of advanced disease is alcohol-associated hepatitis (AH) presenting with rapid onset or worsening of jaundice, and acute on chronic liver failure in severe forms conveying a 1-month mortality risk of 20%–50%. The model for end stage disease score is the most accurate score to stratify AH severity (>20 defined as severe disease). Corticosteroids are currently the only available therapeutic with proven efficacy for patients with severe AH, providing survival benefit at 1 month in 50%–60% of patients. Abstinence of alcohol use, a crucial determinant of long-term outcomes, is challenging to achieve in ALD patients with concurrent alcohol use disorder (AUD). As patients with ALD are rarely treated for AUD, strategies are needed to overcome barriers to AUD treatment in patients with ALD and to promote a multidisciplinary integrated care model with hepatology, addiction medicine providers, and social workers to comprehensively manage the dual pathologies of liver disease and of AUD. Liver transplantation, a definitive treatment option in patients with advanced cirrhosis, should be considered in selected patients with AH, who are unresponsive to medical therapy and have a low risk of relapse to posttransplant alcohol use. Level of evidence and strength of recommendations were evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations system. This guideline was developed under the American College of Gastroenterology Practice Parameters Committee.
Diagnostic Performance of a Fecal Calprotectin Assay as a Biomarker for Mayo Endoscopic Subscore in Ulcerative Colitis: Result From a Tertiary Referral Center
Suttichaimongkol, Tanita , Coelho–Prabhu, Nayantara , Bruining, David H. , Snyder, Melissa R. , Tariq, Raseen , Coelho-Prabhu, Nayantara , Tariq, Raseen , Loftus, Edward V.

Inflammatory Bowel Diseases | January 4, 2024 | Volume: 30 | Issue: 12 | Pages: 2347-2355

10.1093/ibd/izae005 | PMID 38309716 Get It

Abstract Background Fecal calprotectin (FC) is a promising biomarker for assessing ulcerative colitis (UC) endoscopic activity. However, the optimal FC cutoff to identify each Mayo endoscopic subscore (MES) remains inconclusive. Methods The electronic medical records of 177 adult UC patients evaluated at Mayo Clinic Rochester from January 2017 to March 2023 were retrospectively reviewed, obtaining clinical data and US-based Werfen Diagnostics FC levels collected within 30 days before colonoscopy or flexible sigmoidoscopy. Three independent inflammatory bowel disease specialist endoscopists blindly reviewed the most severe endoscopic images for grading MES. Results The median interval between FC collection and endoscopy was 2 days. Fecal calprotectin showed strong positive correlations with MES (Spearman’s r = 0.709; P < .01) and other clinical parameters. Fecal calprotectin cutoff of 60 mcg/g effectively distinguished MES 0 from MES 1-3 (sensitivity, 0.78; specificity, 0.97; area under the receiver operating characteristic curve [AUC], 0.901) and predicted clinical remission (Total Mayo Score ≤2 and no subscore >1; sensitivity, 0.83; specificity, 0.98; AUC, 0.921). Fecal calprotectin cutoff of 110 mcg/g effectively differentiated MES 0-1 from MES 2-3 (sensitivity, 0.86; specificity, 0.87; AUC, 0.915), while a cutoff of 310 mcg/g distinguished MES 0-2 from MES 3 (sensitivity, 0.80; specificity, 0.76; AUC, 0.820). Conclusions This study supports the reliability and applicability of FC as a valuable marker of endoscopic inflammation, particularly in distinguishing MES 0 from MES 1-3 using the FC cutoff of 60 mcg/g. Sensitivity analysis demonstrated robust results.
Leveraging GWAS: Path to Prevention?
Winham, Stacey J. , Sherman, Mark E. , Winham, Stacey J , Sherman, Mark E

Cancer Prevention Research | January 4, 2024 | Volume: 17 | Issue: 1 | Pages: 13-18

10.1158/1940-6207.capr-23-0336 | PMID 38173393 Get It

AbstractDeveloping novel cancer prevention medication strategies is important for reducing mortality. Identification of common genetic variants associated with cancer risk suggests the potential to leverage these discoveries to define causal targets for cancer interception. Although each risk variant confers small increases in risk, researchers propose that blocking those that produce causal carcinogenic effects might have large impacts on cancer prevention. While a promising concept, we describe potential hurdles that may need to be scaled to reach this goal, including: (i) understanding the complexity of risk; (ii) achieving statistical power in studies with binary outcomes (cancer development: yes or no); (iii) characterization of cancer precursors; (iv) heterogeneity of cancer subtypes and the populations in which these diseases occur; (v) impact of static genetic markers across complex events of the life course; (vi) defining gene–gene and gene–environment interactions and (vii) demonstrating functional effects of markers in human populations. We assess short-term prospects for this research against the backdrop of these challenges and the potential to prevent cancer through other means.See related commentary by Peters and Tomlinson, p. 7
Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States : Recommendations from a panel of experts
Karam, Chafic , Mauermann, Michelle L. , Ajroud‐Driss, Senda , Brannagan, Thomas H., Polydefkis, Michael , Mauermann, Michelle L , Karam, Chafic , González-Duarte, Alejandra , Kaku, Michelle C.

Muscle & Nerve | January 4, 2024 | Volume: 69 | Issue: 3 | Pages: 273-287

10.1002/mus.28026 | PMID 38174864 Get It

Abstract Hereditary transthyretin (ATTRv; v for variant) amyloidosis is a rare, multisystem, progressive, and fatal disease in which polyneuropathy is a cardinal manifestation. Due to a lack of United States (US)‐specific guidance on ATTRv amyloidosis with polyneuropathy, a panel of US‐based expert clinicians convened to address identification, monitoring, and treatment of this disease. ATTRv amyloidosis with polyneuropathy should be suspected in unexplained progressive neuropathy, especially if associated with systemic symptoms or family history. The diagnosis is confirmed through genetic testing, biopsy, or cardiac technetium‐based scintigraphy. Treatment should be initiated as soon as possible after diagnosis, with gene‐silencing therapeutics recommended as a first‐line option. Consensus is lacking on what represents “disease progression” during treatment; however, the aggressive natural history of this disease should be considered when evaluating the effectiveness of any therapy.
Updates in hyponatremia and hypernatremia
Saba, Leslie , Hanna, Christian , Creo, Ana L. , Saba, Leslie , Hanna, Christian

Current Opinion in Pediatrics | January 4, 2024 | Volume: 36 | Issue: 2 | Pages: 219-227

10.1097/mop.0000000000001324 | PMID 38174733 Get It

Purpose of review Hyponatremia and hypernatremia are commonly encountered electrolyte abnormalities that require timely and careful intervention, as they can be associated with significant morbidity and mortality. Recent findings This review article addresses the etiology, presentation, diagnosis, and management of both hyponatremia and hypernatremia, emphasizing the latest advancements and emerging trends in pediatric care. Summary A methodical approach is needed to accurately assess and treat hyponatremia and hypernatremia. Both conditions continue to rely on serum and urine testing, however newer tests such as copeptin and stimulated testing may hold promise to further refine testing in the future.
Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
Park, Jung Eun , Nguyen, Vy H. , Tsai, Pei‐Chien , Toyoda, Hidenori , Leong, Jennifer , Guy, Jennifer , Huang, Chung‐Feng , Yasuda, Satoshi , Abe, Hiroshi , Hsu, Yao‐Chun , Tseng, Cheng‐Hao , Liu, Joanne, Chen, Yao‐Li , Lin, Ping‐Yi , Yoshimaru, Yoko , Ishigami, Masatoshi , Enomoto, Masaru , Tamori, Akihiro , Uojima, Haruki , Wang, Xiao Zhong, Xu, Qiang , Takahashi, Hirokazu , Eguchi, Yuichiro , Inoue, Kaori , Zhao, Wen , Barnett, Scott D. , Maeda, Mayumi , Cheung, Ramsey , Landis, Charles , Tanaka, Yasuhito , Roberts, Lewis R. , Schwartz, Myron , Yu, Ming‐Lung , Nguyen, Mindie H. , Yeh, Ming-Lun , Huang, C-F , Tseng, Cheng-Hao , Jun, D W , Ogawa, Eiichi , Huang, Daniel Q , Dai, Chia-Yen , Kumada, Takashi , Yu, M-L , Nguyen, Mindie H , Roberts, Lewis R , Huang, Daniel Q. , Chuang, Wan‐Long , Huang, Jee‐Fu

Alimentary Pharmacology & Therapeutics | January 4, 2024 | Volume: 59 | Issue: 6 | Pages: 742-751

10.1111/apt.17863 | PMID 38173278 Get It

SummaryBackgroundRacial and ethnic disparities exist for hepatitis C virus (HCV) treatment and hepatocellular carcinoma (HCC) survival.AimTo evaluate the impact of HCV treatment on such disparities.MethodsIn a retrospective cohort study, we analysed 6069 patients with HCV‐related HCC (54.2% Asian, 30.1% White, 8.5% Black, and 7.3% Hispanic) from centres in the United States and Asia.ResultsThe mean age was 61, 60, 59 and 68, respectively, for White, Black, Hispanic and Asian patients. Black patients were most likely to have Barcelona Clinic Liver Cancer stage D, vascular invasion and distant metastasis (23% vs. 5%–15%, 20% vs. 10%–17% and 10% vs. 5%–7%, respectively; all p < 0.0001). Treatment rate with direct‐acting antiviral agents (DAA) was 35.9% for Asian, 34.9% for White, 30.3% for Hispanic (30.3%), and 18.7% for Black patients (p < 0.0001). Among those untreated or without sustained virologic response (SVR), 10‐year survival rates were 35.4, 27.5, 19.3 and 14.0, respectively, for Asian, Hispanic, White and Black patients (p < 0.0001). There were no statistically significant differences among those with SVR (p = 0.44). On multivariable analysis adjusted for relevant confounders, there was no statistically significant association between survival and being Hispanic (aHR: 0.68, p = 0.26) or Black (aHR: 1.18, p = 0.60) versus White. There was a significant association between being Asian American and survival (aHR: 0.24, p = 0.001; non‐U.S. Asian: aHR: 0.66, p = 0.05), and for SVR (aHR: 0.30, p < 0.0001).ConclusionDAA treatment rates were suboptimal. Racial and ethnic disparities resolved with HCV cure. Early diagnosis and improved access to HCV treatment is needed for all patients with HCV infection.
Toxicity Studies of Cardiac-Targeting Peptide Reveal a Robust Safety Profile
Sahagun, Daniella, Lopuszynski, Jack , Feldman, Kyle S., Pogodzinski, Nicholas, Zahid, Maliha , Sahagun, Daniella A, Lopuszynski, Jack B, Zahid, Maliha

Pharmaceutics | January 4, 2024 | Volume: 16 | Issue: 1 | Pages: 73

10.3390/pharmaceutics16010073 | PMID 38258084 Get It

Targeted delivery of therapeutics specifically to cardiomyocytes would open up new frontiers for common conditions like heart failure. Our prior work using a phage display methodology identified a 12-amino-acid-long peptide that selectively targets cardiomyocytes after an intravenous injection in as little as 5 min and was hence termed a cardiac-targeting peptide (CTP: APWHLSSQYSRT). CTP has been used to deliver imaging agents, small drug molecules, photosensitizing nanoparticles, exosomes, and even miRNA to cardiomyocytes. As a natural extension to the development of CTP as a clinically viable cardiac vector, we now present toxicity studies performed with the peptide. In vitro viability studies were performed in a human left ventricular myocyte cell line with 10 µM of Cyanine-5.5-labeled CTP (CTP-Cy5.5). In vitro ion channel profiles were completed for CTP followed by extensive studies in stably transfected cell lines for several GPCR-coupled receptors. Positive data for GPCR-coupled receptors were interrogated further with RT-qPCRs performed on mouse heart tissue. In vivo studies consisted of pre- and post-blood pressure monitoring acutely after a single CTP (10 mg/Kg) injection. Further in vivo toxicity studies consisted of injecting CTP (150 µg/Kg) in 60, 6-week-old, wild-type CD1, male/female mice (1:1), with cohorts of mice euthanized on days 0, 1, 2, 7, and 14 with inhalational CO2, followed by blood collection via cardiac puncture, complete blood count analysis, metabolic profiling, and finally, liver, renal, and thyroid studies. Lastly, mouse cardiac MRI was performed immediately before and after CTP (150 µg/Kg) injection to assess changes in cardiac size or function. Human left ventricular cardiomyocytes showed no decrease in viability after a 30 min incubation with CTP-Cy5.5. No significant activation or inhibition of any of seventy-eight protein channels was observed other than OPRM1 and COX2 at the highest tested concentration, neither of which were expressed in mouse heart tissue as assessed using RT-qPCR. CTP (10 mg/Kg) injections led to no change in blood pressure. Blood counts and chemistries showed no evidence of significant hematological, hepatic, or renal toxicities. Lastly, there was no difference in cardiac function, size, or mass acutely in response to CTP injections. Our studies with CTP showed no activation or inhibition of GPCR-associated receptors in vitro. We found no signals indicative of toxicity in vivo. Most importantly, cardiac functions remained unchanged acutely in response to CTP uptake. Further studies using good laboratory practices are needed with prolonged, chronic administration of CTP conjugated to a specific cargo of choice before human studies can be contemplated.
Adult Congenital Heart Disease in the Emergency Department
Lindor, Rachel A. , Heller, Kim, Hodgson, Nicole R. , Kishi, Patrick , Monas, Jessica , Thomas, Aaron , Urumov, Andrej , Walker, Laura , Majdalany, David , Urumov, Andrej , Walker, Laura E , Majdalany, David S , Lindor, Rachel A , Rappaport, Douglas , Thomas, Aaron

Journal of Personalized Medicine | January 4, 2024 | Volume: 14 | Issue: 1 | Pages: 66

10.3390/jpm14010066 | PMID 38248767 Get It

While congenital heart disease historically was a pathology primarily restricted to specialized pediatric centers, advances in technology have dramatically increased the number of people living into adulthood, the number of complications faced by these patients, and the number of patients visiting non-specialized emergency departments for these concerns. Clinicians need to be aware of the issues specific to patients’ individual congenital defects but also have an understanding of how typical cardiac pathology may manifest in this special group of patients. This manuscript attempts to provide an overview of this diverse but increasingly common group of adult patients with congenital heart diseases, including a review of their anatomical variants, the complications they face at the highest rates, and ways that emergency physicians may need to manage these patients differently to avoid causing harm.
Patient reported QOL and EV‐ICD: Response to letter from Kataoka and Imamura (2024)
Harrell, Rebecca , Crozier, Ian , Murgatroyd, Francis , Manlucu, Jaimie , Knight, Bradley P. , Leclercq, Christophe , Birgersdotter‐Green, Ulrika , Wiggenhorn, Christopher, Hilleren, Gregory, Friedman, Paul A. , Sears, Samuel F , Harrell, Rebecca , Crozier, Ian , Manlucu, Jaimie , Friedman, Paul A , Knight, Bradley P , Sears, Samuel F. , Boersma, Lucas V.A.

Journal of Cardiovascular Electrophysiology | January 4, 2024 | Volume: 35 | Issue: 2 | Pages: 371-372

10.1111/jce.16175 | PMID 38172587 Get It

Comorbid neurotrauma increases neurodegenerative-relevant cognitive, motor, and autonomic dysfunction in patients with rapid eye movement sleep behavior disorder: a substudy of the North American Prodromal Synucleinopathy Consortium
Ligman, Brittany R. , Bryant‐Ekstrand, Mohini , Keil, Allison , Powers, Katherine , Olivo, Cosette, Neilson, Lee E. , Pelletier, Amélie , Gagnon, Jean‐François , Liu, Lang , Forsberg, Leah K. , Fields, Julie A. , Ross, Owen A. , Howell, Michael J. , McLeland, Jennifer , Criswell, Susan R. , Miglis, Mitchell G. , Lee‐Iannotti, Joyce , Ju, Yo‐El S. , Lim, Miranda M. , Locke, Jessica, Amudson-Huffmaster, Sommer, Brushaber, Nellie, Chung, Jae Woo , Kam, Joshua De , Fischbach, Ellen, Ekelmans, Adrian , Keane, Marissa, Kraft, Ruth, MacKinnon, Colum D. , Miner-Rose, Daeva, Murphy, Samantha , Rivera, Adreanne, Sanchez, Sarahmay, Summers, Rebekah L. S. , Tiegan, Luke, Taylor, Leah, Timm, Paul, Tucker, Kelsey, Yu, Erik, Tran, Peter , Galasko, Douglas, Mignot, Emmanuel , Elliott, Jonathan E , Powers, Katherine , Neilson, Lee E , Gan-Or, Ziv , St Louis, E K , Ross, Owen A , Huddleston, Daniel E , Bliwise, Donald L , Avidan, Alon Y , Criswell, Susan R , During, Emmanuel , Miglis, Mitchell G , Boeve, Brad , Lim, Miranda M , Howell, Michael J , Elliott, Jonathan E. , Postuma, Ronald B. , Gan‐Or, Ziv , Yu, Eric , Louis, Erik K. St. , Huddleston, Daniel E. , Bliwise, Donald L. , Avidan, Alon Y. , Schenck, Carlos H. , Videnovic, Aleksandar , Shprecher, David , Boeve, Bradley F. , Duff, Kevin , Choudhury, Parichita , Stauder, Matthew J. , Taylor, Leah

SLEEP | January 4, 2024 | Volume: 47 | Issue: 6 | Pages: No page available

10.1093/sleep/zsae007 | PMID 38181205 Get It

Abstract Study Objectives Rapid eye movement sleep behavior disorder (RBD) is strongly associated with phenoconversion to an overt synucleinopathy, e.g. Parkinson’s disease (PD), Lewy body dementia, and related disorders. Comorbid traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD)—henceforth “neurotrauma” (NT)—increase the odds of RBD by ~2.5-fold and are associated with an increased rate of service-connected PD in Veterans. Thus, RBD and NT are both independently associated with PD; however, it is unclear how NT influences neurological function in patients with RBD. Methods Participants ≥18 years with overnight polysomnogram-confirmed RBD were enrolled between 8/2018 to 4/2021 through the North American Prodromal Synucleinopathy Consortium. Standardized assessments for RBD, TBI, and PTSD history, as well as cognitive, motor, sensory, and autonomic function, were completed. This cross-sectional analysis compared cases (n = 24; RBD + NT) to controls (n = 96; RBD), matched for age (~60 years), sex (15% female), and years of education (~15 years). Results RBD + NT reported earlier RBD symptom onset (37.5 ± 11.9 vs. 52.2 ± 15.1 years of age) and a more severe RBD phenotype. Similarly, RBD + NT reported more severe anxiety and depression, greater frequency of hypertension, and significantly worse cognitive, motor, and autonomic function compared to RBD. No differences in olfaction or color vision were observed. Conclusions This cross-sectional, matched case:control study shows individuals with RBD + NT have significantly worse neurological measures related to common features of an overt synucleinopathy. Confirmatory longitudinal studies are ongoing; however, these results suggest RBD + NT may be associated with more advanced neurological symptoms related to an evolving neurodegenerative process.